Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Quick ratio

Quick ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.1×0.0×
Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1×+0.1×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
3.2×-2.4×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
18.6×-4.0×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
22.1×+2.2×

Other financials

Income statement

See full
Revenue-—
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0×0.0×
Current ratio5.7×-38.5×

Where this comes from

Calculated from Viking Therapeutics’s reported figures.

quick assets/total current liabilities=5.7×

Based on the most recent quarter.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's quick ratio?
Viking Therapeutics (VKTX) reported quick ratio of 5.7× in Q1 2026.
How has Viking Therapeutics's quick ratio changed year-over-year?
Viking Therapeutics's quick ratio decreased by 87.1% year-over-year, from 44.2× to 5.7×.
What is the long-term trend for Viking Therapeutics's quick ratio?
Over 5 years (2020 to 2025), Viking Therapeutics's quick ratio has grown at a -15.1% compound annual growth rate (CAGR), from 21.1× to 9.3×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.